Over the years, I found Canaccord is not bad at lithium spodumene concentrate price forecast. They have been sticky their long term SC6 at US$1,500/t for last crazy spike.
Their cost estimates are conservative, which is good for readers, imo.
They had a higher estimates of capex and opex for Liontown before last update in September 2023, credit to them. They estimated AZS' Andover capex to be $1B, operation cost to be US$538/t, comparable to LTR's updated costs of US$590/t. The updated costs are released after the underground contract awarded.
![]()
SQM and Gina are currently buying 60% of the Andover project (around 5 years away from the production) for $1.7B, valuing the whole project at $2.8B.
LTR, currently market cap $2.2B, including spending $1B to develop and build the mine, if less the $1B development costs/capex, LTR is currently valued at $1.5B (added back $300m debt).
So more advantage stage LTR is only valued at $1.5B Vs early stage Andover at $2.8B.
Let's look forward, current LTR cash reserve is sufficient to complete the construction, valuation to construction completion is $2.5B; 100% of the Andover project is valued at $2.8B before construction, adds $1B capex, valuation to construction completion is $3.8B;
LTR $2.5B Vs Andover $3.8B.
More advanced, few years ahead, but valuation is 52% less.
Always DYOR, all imo.
- Forums
- ASX - By Stock
- LTR
- Ann: Project and Funding Update
Ann: Project and Funding Update, page-591
-
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add LTR (ASX) to my watchlist
|
|||||
Last
97.0¢ |
Change
-0.030(3.00%) |
Mkt cap ! $2.352B |
Open | High | Low | Value | Volume |
$1.03 | $1.03 | 96.5¢ | $13.68M | 13.82M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
9 | 76446 | 96.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
97.5¢ | 50000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 375 | 1.015 |
3 | 12008 | 1.000 |
4 | 11735 | 0.980 |
5 | 13502 | 0.975 |
11 | 30050 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.950 | 10124 | 2 |
0.965 | 2203 | 3 |
0.970 | 407 | 3 |
0.975 | 50465 | 2 |
0.980 | 44760 | 4 |
Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
Featured News
LTR (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online